看屋買房賣房和房仲情報站論文書籍站
FloTrac monitor的問題，透過圖書和論文來找解法和答案更準確安心。 我們查出實價登入價格、格局平面圖和買賣資訊
長庚大學 臨床醫學研究所 鄭美玲、余黃平所指導 蔡欣怡的 從臨床血液動力學到基礎代謝體學探討肝臟器官移植 （2018），提出FloTrac monitor關鍵因素是什麼，來自於肝臟移植、生物標記、血液動力學、代謝體學。
而第二篇論文國立陽明大學 急重症醫學研究所 陳理維、葉育彰所指導 張雅斐的 比較外科重症病人使用右美托咪定和普洛福對血流動力學的影響 （2017），提出因為有 腹部手術、心臟輸出指數、右美托咪定、普洛福、鎮靜的重點而找出了 FloTrac monitor的解答。
從臨床血液動力學到基礎代謝體學探討肝臟器官移植
為了解決FloTrac monitor 的問題，作者蔡欣怡 這樣論述：
指導教授推薦書……………………………………………………口試委員審定書……………………………………………………誌謝………………………………………………………………… iii中文摘要……………………………………………………………. vABSTRACT………………………………………………………… viiABBREVIATION………………………………………………….. ixChapter 1 Introduction on Liver Transplantation......................... 11.1 Types of Liver Tra
nsplantation……………………………... 21.1.1 De Novo Malignancies after Liver Transplantation from Taiwan’s Database……………………………. 41.1.2 Cardiovascular Disease Risks after Liver Transplantation from Taiwan’s Database……………. 71.2 Selection Criteria on Recipient……………………………... 101.3 Selectio
n Criteria on Living Donor………………………… 121.4 Intraoperative Monitoring and Management……………….. 141.4.1 Arterial Waveform Monitoring –FloTrac…………… 161.4.2 Electrical Velocimetry Monitoring System - Aesculon™………………………………………….. 181.5 Primary Graft Dysfunction…………………………………. 24Cha
pter 2 Introduction to Instrumentation in Metabolomic Analysis…………………………………………………………….. 272.1 Metabolomics……………………………………………….. 272.2 Nuclear Magnetic Resonance Spectroscopy……………………………………………………. 292.3 Mass Spectrometry…………………………………………. 312.4 Data Analysis……………………………………………….. 34Chapter
3 A Lipidomic Study of Early Allograft Dysfunction In Living Donor Liver Transplantation……………………………... 383.1 Methods and Materials……………………………………… 403.1.1 Patient Selection……………………………………… 403.1.2 Blood Samples……………………………………….. 413.1.3 NMR analysis of the plasma…………………………. 413.1.4 Liqui
d Chromatography coupled with Mass Spectrometry based Lipidomic…………………………….. 433.1.5 Ultra-performance liquid chromatography (UPLC)-based amino acid measurement…………………... 453.1.6 Statistical analysis……………………………………. 463.2 Results………………………………………………………. 473.2.1 Demographics and Clinical Dat
a…………………….. 473.2.2 Change in circulatory amino acid profiles in recipients with EAD……………………………………….. 483.2.3 Changes in NMR plasma profiles in recipients with EAD………………………………………………………… 483.2.4 Changes in circulatory lipid profiles in recipients with EAD………………………………………………………… 493.2.5 Dis
criminative ability of potential biomarkers for EAD and in-hospital mortality…………………………… 493.2.6 External validation of lipidomic profiling as prediction of EAD, long hospital stay and in-hospital mortality……………………………………………………. 503.3 Discussion……….………………………………………….. 513.3.1 Amino Acid………………
………………………...… 513.3.2 Lipids…………………………………………………. 523.3.3 Bilirubin……………………………………………… 55Chapter 4 Conclusion........................................................................ 56Chapter 5 Future Perspectives…………………………………... 59Chapter 6 Figures…………………………………………………. 60Figure 1. Flowchar
t of organ transplant recipients during 1996-201.. 60Figure 2. Flowchart of organ transplant patients during 1996-2011... 61Figure 3. Cumulative probability of any kind of vascular diseasefrom years after organ transplant…………………………………….62Figure 4. Cumulative probability of cardiovascular disease fro
myears after organ transplant…………………………………………..63Figure 5 Cumulative probability of cerebrovascular disease fromyears after organ transplant…………………………………………..64Figure 6. Cumulative probability of peripheral vascular disease fromyears after organ transplant…………………………………………..65Figure 7. Cumulative pro
bability of deep vein thrombosis fromyears after organ transplant………………………………………….66Figure 8. Modified formula of cardiac output analyses for theFloTrac algorithm…………………………………………………… 67Figure 9. Bland-Altman plot for COEv and COPAC………………… 68Figure 10. Four-quadrant plot for comparing changes in COEv
andCOPAC……………………………………………………………….69Figure 11. Schematic of the electrospray ionization process………... 70Figure 12. Flow diagram of the patient selection, allocation andanalysis……………………………………………………………… 71Figure 13. 1H NMR plasma profile model………………………….. 72Figure 14. 1H NMR plasma profile model………………
………….. 73Figure 15. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients inOPLS-DA plot……………………………………………………… 74Figure 16. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients in 75S-plot……………………………………
……………………………Figure 17. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients by classpermutation analysis………………………………………………… 76Figure 18. Prediction of early allograft dysfunction in study cohort... 77Figure 19. Prediction of long hospital stay in stud
y cohort…………. 78Figure 20. Prediction of all-cause in-hospital mortality in studycohort…………………………………………………………….......79Figure 21. Prediction of early allograft dysfunction in validationcohort………………………………………………………………...80Figure 22. Prediction of long hospital stay in validation cohort…….. 81Figure 23
. Prediction of all-cause in-hospital mortality in validationcohort ………………………………………………………………..82Figure 24. Schematic illustration of metabolic disturbancesassociated with poor outcomes of liver transplants………………… 83Chapter 7 Tables………………………..………………………….. 84Table 1. Risk of malignancies in liver tran
plant recipients………….. 84Table 2. Risk of vascular disease in liver transplant recipients……... 86Table 3. Summary of clinical data for living donor livertransplantation recipients……………………………………………. 87Table 4. Biochemical data for the patients before and after livertransplantation……………………………………………………
….88Table 5. Concentrations of amino acids at T6 in study group………. 90Table 6. A List of metabolites that discriminated the EAD from thenon-EAD groups …………………………………………………….91Table 7. Receiver operating characteristic (ROC) curve analysis forindividual metabolites in study and validation group……………….
93Table 8. Demographic details from the validation population……… 94Table 9. Biochemical details from the validation study population… 95Chapter 8 References…….………………………………………... 96Appendix……………………………………………………………. 112List of FiguresFigure 1. Flowchart of organ transplant recipients during 1996-201..
60Figure 2. Flowchart of organ transplant patients during 1996-2011... 61Figure 3. Cumulative probability of any kind of vascular diseasefrom years after organ transplant…………………………………….62Figure 4. Cumulative probability of cardiovascular disease fromyears after organ transplant…………………………………………..63Fi
gure 5 Cumulative probability of cerebrovascular disease fromyears after organ transplant…………………………………………..64Figure 6. Cumulative probability of peripheral vascular disease fromyears after organ transplant…………………………………………..65Figure 7. Cumulative probability of deep vein thrombosis fromyears after or
gan transplant………………………………………….66Figure 8. Modified formula of cardiac output analyses for theFloTrac algorithm…………………………………………………… 67Figure 9. Bland-Altman plot for COEv and COPAC………………… 68Figure 10. Four-quadrant plot for comparing changes in COEv andCOPAC……………………………………………………………….69Figure 11. Sche
matic of the electrospray ionization process………... 70Figure 12. Flow diagram of the patient selection, allocation andanalysis……………………………………………………………… 71Figure 13. 1H NMR plasma profile model………………………….. 72Figure 14. 1H NMR plasma profile model………………………….. 73Figure 15. Plasma samples analyzed by LC-M
S in electrospraypositive ion mode, comparing EAD and nonEAD recipients inOPLS-DA plot……………………………………………………… 74Figure 16. Plasma samples analyzed by LC-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients inS-plot………………………………………………………………… 75Figure 17. Plasma samples analyzed by LC
-MS in electrospraypositive ion mode, comparing EAD and nonEAD recipients by classpermutation analysis………………………………………………… 76Figure 18. Prediction of early allograft dysfunction in study cohort... 77Figure 19. Prediction of long hospital stay in study cohort…………. 78Figure 20. Prediction of all-cause
in-hospital mortality in studycohort…………………………………………………………….......79Figure 21. Prediction of early allograft dysfunction in validationcohort………………………………………………………………...80Figure 22. Prediction of long hospital stay in validation cohort…….. 81Figure 23. Prediction of all-cause in-hospital mortality in
validationcohort ………………………………………………………………..82Figure 24. Schematic illustration of metabolic disturbancesassociated with poor outcomes of liver transplants………………… 83List of TablesTable 1. Risk of malignancies in liver tranplant recipients………….. 84Table 2. Risk of vascular disease in liver transplant
recipients……... 86Table 3. Summary of clinical data for living donor livertransplantation recipients……………………………………………. 87Table 4. Biochemical data for the patients before and after livertransplantation……………………………………………………….88Table 5. Concentrations of amino acids at T6 in study group………. 90Table 6.
A List of metabolites that discriminated the EAD from thenon-EAD groups …………………………………………………….91Table 7. Receiver operating characteristic (ROC) curve analysis forindividual metabolites in study and validation group……………….93Table 8. Demographic details from the validation population……… 94Table 9. Bio
chemical details from the validation study population… 95
比較外科重症病人使用右美托咪定和普洛福對血流動力學的影響
為了解決FloTrac monitor 的問題，作者張雅斐 這樣論述：
背景與目的： 右美托咪定（Dexmedetomidine）和普洛福（Propofol）可能會導致低血壓或心搏過緩，本研究旨在比較外科加護病房接受腹部手術的病人使用右美托咪定和普洛福對血流動力學之影響和臨床的結果。材料與方法： 納入研究的病人隨機分配到右美托咪定組或普洛福組，利用胸部生物電抗(Bioreactance)技術的連續非侵入性心輸出量監測儀器(Non-Invasive Cardiac Output Monitor, NICOM)，檢測心臟輸出指數(cardiac index, CI)。比較兩組病人的心跳速率、血壓值、鴉片類止痛劑使用量、尿液輸出量、譫妄發生率、加護病房住院
天數和總住院天數，並比較心搏過緩、低血壓和嚴重低心臟輸出指數的發生率。結果： 本研究對象總共有60位病人，在比較心跳速率和平均動脈壓上，右美托咪定組顯著低於普洛福組，但是兩組之間的心臟輸出指數未達到統計學顯著的差異（心臟輸出指數在右美托咪定組為3.1 L/min/m2 [95%信賴區間為2.8-3.3]；相較於普洛福組為3.2 L/min/m2 [95%信賴區間為 2.9-3.5], P值= 0.578），心搏過緩、低血壓和嚴重低心臟輸出指數的發生率在兩組之間亦未達顯著的差異。結論： 比較外科成人加護病房接受腹部手術的病人在右美托咪定組和普洛福組，兩組於心臟輸出指數未達顯著的差異。